Literature DB >> 20107010

Development of a bead immunoassay to measure Vi polysaccharide-specific serum IgG after vaccination with the Salmonella enterica serovar Typhi Vi polysaccharide.

Herman F Staats1, Shaun M Kirwan, Carol C Whisnant, James L Stephenson, Diane K Wagener, Partha P Majumder.   

Abstract

Vi polysaccharide from Salmonella enterica serotype Typhi is used as one of the available vaccines to prevent typhoid fever. Measurement of Vi-specific serum antibodies after vaccination with Vi polysaccharide by enzyme-linked immunosorbent assay (ELISA) may be complicated due to poor binding of the Vi polysaccharide to ELISA plates resulting in poor reproducibility of measured antibody responses. We chemically conjugated Vi polysaccharide to fluorescent beads and performed studies to determine if a bead-based immunoassay provided a reproducible method to measure vaccine-induced anti-Vi serum IgG antibodies. Compared to ELISA, the Vi bead immunoassay had a lower background and therefore a greater signal-to-noise ratio. The Vi bead immunoassay was used to evaluate serum anti-Vi IgG in 996 subjects from the city of Kolkata, India, before and after vaccination. Due to the location being one where Salmonella serotype Typhi is endemic, approximately 45% of the subjects had protective levels of anti-Vi serum IgG (i.e., 1 microg/ml anti-Vi IgG) before vaccination, and nearly 98% of the subjects had protective levels of anti-Vi serum IgG after vaccination. Our results demonstrate that a bead-based immunoassay provides an effective, reproducible method to measure serum anti-Vi IgG responses before and after vaccination with the Vi polysaccharide vaccine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20107010      PMCID: PMC2837971          DOI: 10.1128/CVI.00354-09

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  42 in total

1.  The role of epidemiology in the introduction of vi polysaccharide typhoid fever vaccines in Asia.

Authors:  Camilo J Acosta; Claudia M Galindo; R Leon Ochiai; M Carolina Danovaro-Holliday; Anne-Laure Page; Vu Dinh Thiem; Jin Kyoung Park; Eunsik Park; Hyewon Koo; Xuan-Yi Wang; Remon Abu-Elyazeed; Mohammad Ali; M John Albert; Bernard Ivanoff; Tikki Pang; Zhi-Yi Xu; John D Clemens
Journal:  J Health Popul Nutr       Date:  2004-09       Impact factor: 2.000

2.  Capric acid and hydroxypropylmethylcellulose increase the immunogenicity of nasally administered peptide vaccines.

Authors:  Sushila K Nordone; James W Peacock; Shaun M Kirwan; Herman F Staats
Journal:  AIDS Res Hum Retroviruses       Date:  2006-06       Impact factor: 2.205

3.  Appropriate calibration curve fitting in ligand binding assays.

Authors:  John W A Findlay; Robert F Dillard
Journal:  AAPS J       Date:  2007-06-29       Impact factor: 4.009

4.  Typhoid vaccines: WHO position paper.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2008-02-08

Review 5.  Rethinking typhoid fever vaccines: implications for travelers and people living in highly endemic areas.

Authors:  Jennifer A Whitaker; Carlos Franco-Paredes; Carlos del Rio; Srilatha Edupuganti
Journal:  J Travel Med       Date:  2009 Jan-Feb       Impact factor: 8.490

6.  Development of a fluorescent-bead-based multiplex immunoassay to determine immunoglobulin G subclass responses to Neisseria meningitidis serogroup A and C polysaccharides.

Authors:  Richarda M de Voer; Fiona R M van der Klis; Carla W A M Engels; Ger T Rijkers; Elisabeth A Sanders; Guy A M Berbers
Journal:  Clin Vaccine Immunol       Date:  2008-06-11

7.  Mast cell activators: a new class of highly effective vaccine adjuvants.

Authors:  James B McLachlan; Christopher P Shelburne; Justin P Hart; Salvatore V Pizzo; Rajen Goyal; Rhea Brooking-Dixon; Herman F Staats; Soman N Abraham
Journal:  Nat Med       Date:  2008-04-20       Impact factor: 53.440

8.  Future vaccine development at NICHD.

Authors:  John B Robbins; Rachel Schneerson
Journal:  Ann N Y Acad Sci       Date:  2004-12       Impact factor: 5.691

9.  Qualification and performance characteristics of a quantitative enzyme-linked immunosorbent assay for human lgG antibodies to anthrax lethal factor antigen.

Authors:  Cheryl L Selinsky; Vanessa D Whitlow; Larry R Smith; David C Kaslow; Holly M Horton
Journal:  Biologicals       Date:  2006-10-30       Impact factor: 1.856

Review 10.  Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials.

Authors:  Abigail Fraser; Mical Paul; Elad Goldberg; Camilo J Acosta; Leonard Leibovici
Journal:  Vaccine       Date:  2007-09-04       Impact factor: 3.641

View more
  4 in total

1.  Genomics of immune response to typhoid and cholera vaccines.

Authors:  Partha P Majumder
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-06-19       Impact factor: 6.237

2.  Evaluation of vaccine-induced antibody responses: impact of new technologies.

Authors:  Daniel J Zaccaro; Diane K Wagener; Carol C Whisnant; Herman F Staats
Journal:  Vaccine       Date:  2013-04-11       Impact factor: 3.641

3.  A human IgG anti-Vi reference for Salmonella typhi with weight-based antibody units assigned.

Authors:  Shousun C Szu; Steven Hunt; Guilin Xie; John B Robbins; Rachel Schneerson; Rajesh K Gupta; Zhigang Zhao; Xiaomei Tan
Journal:  Vaccine       Date:  2013-02-17       Impact factor: 3.641

4.  Fifth Percentile Cutoff Values for Antipneumococcal Polysaccharide and Anti-Salmonella typhi Vi IgG Describe a Normal Polysaccharide Response.

Authors:  Heidi Schaballie; Barbara Bosch; Rik Schrijvers; Marijke Proesmans; Kris De Boeck; Mieke Nelly Boon; François Vermeulen; Natalie Lorent; Doreen Dillaerts; Glynis Frans; Leen Moens; Inge Derdelinckx; Willy Peetermans; Bjørn Kantsø; Charlotte Svaerke Jørgensen; Marie-Paule Emonds; Xavier Bossuyt; Isabelle Meyts
Journal:  Front Immunol       Date:  2017-05-12       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.